Imatinib and Trametinib for KRAS-mutated Solid Tumor

In this pilot trial, participants with unresectable solid cancers harboring KRAS mutations will be provided with a compassionate treatment if their diseases progress after current standard treatments, or there is no available standard treatment. This trial will evaluate the efficacy and safety of the combination of trametinib and imatinib on chemotherapy refractory solid cancers.

NCT Number	NCT06962254
Lead Sponsor	China Medical University Hospital
Conditions	Solid Tumor Cancer
Enrollment	10 participants
Start Date	2025-05-10
Primary Completion	2028-03-31 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-05-08